Aptevo Therapeutics Closes $35 Million Term Loan Agreement
“The
The MidCap financing provides Aptevo with up to
The first tranche, in the amount of
About
About MidCap Financial
MidCap Financial is a middle-market focused, specialty finance firm that provides senior debt solutions to businesses across all industries. The firm’s years of experience, strong balance sheet, and flexibility make it a lender of choice for companies across all stages of growth and complexity. MidCap Financial’s debt solutions focus in five areas:
- General and healthcare asset-based working capital loans collateralized by third-party accounts receivable and other assets;
- Leveraged loans to companies backed by private equity sponsors;
- Life sciences loans to VC-backed and public pharmaceutical, biotech, and medical device companies;
- Real estate loans on all types of commercial properties, medical office buildings, various types of senior housing and skilled nursing properties; and
- Lender finance term loans or revolvers provided across the consumer and commercial finance sectors.
Additional information about MidCap Financial can be found at www.midcapfinancial.com.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding the potential opportunities and financial impact of the transaction, our technology and related pipeline, collaboration and partnership opportunities and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “forecasts,” “estimates,” “will” and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause our actual
results to differ materially from those indicated by such
forward-looking statements, including possible negative effects on our
business operations, assets or financial results as a result of the
separation; a deterioration in our business or prospects; adverse
developments in our customer-base or markets; adverse developments in
the U.S. or global capital markets, credit markets or economies
generally; and changes in regulatory, social and political conditions.
Additional risks and factors that may affect results are set forth in
our filings with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20160805005089/en/
Source:
Aptevo Therapeutics
Stacey Jurchison, 206-859-6628
Senior
Director, Investor Relations and Corporate Communications
JurchisonS@apvo.com